BSE Pharma Sector Regulatory Filings — May 29, 2026

Standalone revenue grew 9.9% YoY to ₹7,336.75 Cr in FY26, with Q4 profit before exceptional items up 27.3% YoY to ₹380.27 Cr, indicating strong core operational momentum despite large impairment charges

22nd consecutive quarter of YoY growth with Q4 FY26 revenue of ₹2,664 Cr (+10% YoY) and operating EBITDA of ₹682 Cr (+8% YoY), demonstrating consistent execution and network expansion

Full-year consolidated sales grew 11.9% YoY to ₹582 Billion, with Global Innovative Medicines segment surging 20.1% to US$ 354 million, signaling successful specialty pipeline monetization

Consolidated net profit rose 30% YoY to ₹13,618.51 million in FY26, and Q4 net profit surged to ₹3,014.14 million from ₹46.50 million, indicating strong international operations

Excluding oncology, gross revenue grew 15% YoY and 5% QoQ, showing broad-based demand across other specialties

Gross margin improved to 80.8% in Q4 FY26 from prior year, driven by better product mix, a positive sign for profitability

Full-year profit before exceptional items rose 56.3% to ₹1,562.55 Cr, significantly outpacing revenue growth of 9.9%, indicating strong operating leverage

Standalone Q4 FY26 net sales increased 15.6% YoY to ₹22,075.64 million, showing recovery in domestic formulation business

US business declined 1.1% YoY to US$ 459 million due to generic competition, and EBITDA margin compressed to 27.1% from 28.7% YoY, signaling headwinds in key market

Full-year net profit fell 42.5% to ₹650.76 Cr from ₹1,132.52 Cr, impacted by exceptional impairment charges of ₹281.54 Cr, raising concerns about subsidiary/associate performance

Standalone FY26 net loss of ₹2,007.99 million vs profit of ₹16,103.50 million in FY25, driven by exceptional items of ₹18,008.58 million, indicating significant one-time hits

Oncology in-patient revenue share dropped permanently to 21% from 26% due to discontinuation of high-value chemotherapy drugs, a structural headwind to high-margin revenue

Exceptional items of ₹281.54 Cr (₹173 Cr subsidiary impairment + ₹108.54 Cr associate impairment) wiped out 18% of full-year profit before tax, signaling potential overvaluation or underperformance in investments

Standalone exceptional items of ₹18,008.58 million in FY26, exceeding standalone net sales of ₹84,400.99 million by 21%, indicating severe one-time charges that could recur

Permanent 5 percentage point drop in oncology share of inpatient revenue (26% to 21%) due to discontinuation of high-value chemotherapy drugs, impacting high-margin revenue stream

US business declined 1.1% YoY to US$ 459 million due to generic competition, with no immediate catalyst for reversal, and EBITDA margin compressed 160 bps YoY

Standalone Q4 FY26 net sales down 5.2% sequentially from Q3 FY26, and consolidated net sales down 3.3% sequentially, indicating potential demand slowdown

Despite 42.5% decline in net profit, Board recommended dividend of ₹6 per share (600%), which may not be sustainable if impairment charges recur

Average Length of Stay (ALOS) increased 9% YoY temporarily due to simultaneous multi-location capacity rollout, impacting ARPOB and EBITDA per bed

Acquisition of Multicare Pharmaceuticals Philippines delayed from May to July 2026 due to unsatisfied closing conditions, indicating potential deal renegotiation or failure

Acquisition of Organon expected to close in Q4 FY27, posing integration risks and potential earnings dilution in near term

Standalone other equity decreased to ₹2,41,221.04 million from ₹2,44,757.37 million as of March 2025, indicating erosion of shareholder value

With profit before exceptional items up 56.3% YoY and revenue up 9.9%, the core business is firing on all cylinders; the impairment charges appear one-time, offering a potential entry point at depressed valuations

₹1,400 crore investment for a 700-bed greenfield hospital in Lucknow and acquisition of Kalinga Hospital (250 beds) in Bhubaneswar will drive future revenue growth, with occupancy already above 75%

Global Innovative Medicines segment grew 20.1% to US$ 354 million, and gross margin improved to 80.8%, indicating successful shift to high-margin specialty drugs; Organon acquisition could further boost pipeline

Consolidated net profit surged 30% YoY to ₹13,618.51 million, and Q4 net profit jumped to ₹3,014.14 million from ₹46.50 million, signaling strong international recovery

Excluding oncology, gross revenue grew 15% YoY and 5% QoQ, showing strong demand across other specialties; network occupancy above 75% provides pricing power

Standalone Q4 FY26 net sales up 15.6% YoY to ₹22,075.64 million, indicating recovery in domestic formulation business after a weak year

Q4 FY26 forex gain of INR 4,268 million provided a significant boost to earnings, which could continue if rupee remains weak

With dividend of ₹6 per share (600%) and record date of August 7, 2026, investors can lock in a yield; the reappointment of Mr. Prashant Godha ensures leadership continuity

Despite delay, the acquisition of Multicare Pharmaceuticals Philippines provides entry into a growing Southeast Asian market; completion expected in July 2026 could be a near-term catalyst

Scheduled for June 9, 2026, the event could provide clarity on the exceptional items and future strategy, potentially triggering a re-rating

All four companies (Ipca, Glenmark, Max, Sun) reported YoY revenue growth (9.9% to 27.5%), but three (Ipca, Glenmark, Sun) saw profit metrics diverge due to exceptional items or margin compression, highlighting the importance of analyzing core operational performance

Both Ipca Laboratories (₹281.54 Cr) and Glenmark Pharmaceuticals (₹18,008.58 million) reported large exceptional items that significantly impacted standalone profits, a sector-wide theme of impairment charges and one-time costs

Sun Pharma's 20.1% growth in Global Innovative Medicines and Max Healthcare's 15% ex-oncology growth indicate a sector-wide pivot towards high-margin, specialized offerings away from commoditized segments

Max Healthcare's ₹1,400 Cr greenfield investment and Sun Pharma's Organon acquisition signal aggressive capacity expansion, with near-term costs but long-term revenue potential

Both Ipca Laboratories (₹6/share) and Glenmark Pharmaceuticals (₹2.5/share) recommended dividends despite sharp profit declines, indicating a commitment to shareholder returns and confidence in future cash flows

Glenmark's consolidated profit surge (30% YoY) vs standalone loss, and Sun Pharma's US business decline vs Global Innovative Medicines growth, highlight the importance of geographic diversification in mitigating regional headwinds

Scheduled for June 9, 2026, in Mumbai; watch for management commentary on exceptional items, future strategy, and standalone business recovery

Expected completion in July 2026; monitor for any further delays or changes in deal terms that could impact valuation

Expected to close in Q4 FY27; watch for integration updates, regulatory approvals, and potential earnings impact

Monitor for any further impairment in subsidiaries or associates; the reappointment of Mr. Prashant Godha as Executive Director until 2031 provides leadership stability

Watch for any recovery in oncology revenue share or further decline; the permanent nature of the change makes this a key metric to track

Watch for narrowing of the gap between standalone losses and consolidated profits, which would indicate improving domestic operations

Record date is August 7, 2026; investors should ensure they are on the register by this date to receive the ₹6 per share dividend

Monitor Average Length of Stay and occupancy rates in coming quarters to assess if the temporary increase in ALOS normalizes and occupancy remains above 75%